Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Changing Face of Academic Laboratory Medicine-A Decade Later and Beyond.

Clinical chemistry·2025
Same author

Implementation of high-sensitivity troponin with a rapid diagnostic algorithm reduces emergency department length of stay for discharged patients.

Clinical biochemistry·2023
Same author

Predicting Postoperative Troponin in Patients Undergoing Elective Hip or Knee Arthroplasty: A Comparison of Five Cardiac Risk Prediction Tools.

Cardiology research and practice·2022
Same author

"Shaking" the Kidneys Up!

Clinical chemistry·2022
Same author

Serial cardiac biomarkers for risk stratification of patients with COVID-19.

Clinical biochemistry·2022
Same author

Clinical Decision Support Rapidly Improves Test Utilization During a Nationwide Phlebotomy Tube Shortage.

Clinical chemistry·2021

Related Experiment Video

Updated: Jun 12, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

When do new biomarkers make economic sense?

Mitchell G Scott1

  • 1Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. mscott@pathology.wustl.edu

Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum
|June 3, 2010
PubMed
Summary

Evaluating new biomarkers requires assessing both clinical utility and economic benefits. Cost-utility studies, measuring cost per quality-adjusted life year (QALY), are crucial for determining if new tests are cost-effective for healthcare systems.

More Related Videos

Ultrasensitive Detection of Biomarkers by Using a Molecular Imprinting Based Capacitive Biosensor
08:22

Ultrasensitive Detection of Biomarkers by Using a Molecular Imprinting Based Capacitive Biosensor

Published on: February 16, 2018

Related Experiment Videos

Last Updated: Jun 12, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Ultrasensitive Detection of Biomarkers by Using a Molecular Imprinting Based Capacitive Biosensor
08:22

Ultrasensitive Detection of Biomarkers by Using a Molecular Imprinting Based Capacitive Biosensor

Published on: February 16, 2018

Area of Science:

  • Health Economics
  • Clinical Laboratory Science
  • Biomarker Discovery

Background:

  • Cost-effectiveness and cost-utility analyses are standard for drugs and interventions.
  • These economic evaluations are less common for clinical laboratory tests.
  • Rising healthcare costs necessitate economic scrutiny of new biomarkers alongside clinical utility.

Purpose of the Study:

  • To highlight the importance of economic evaluations for new clinical laboratory biomarkers.
  • To explain the methodology and significance of cost-utility studies.
  • To discuss the economic hurdles new biomarkers face before routine adoption.

Main Methods:

  • Review of cost-effectiveness and cost-utility study principles.
  • Explanation of quality-adjusted life year (QALY) as a metric.
  • Discussion of the general cost-effectiveness threshold (USD 50,000 per QALY).

Main Results:

  • New biomarkers must demonstrate clinical usefulness before economic evaluation.
  • Cost-utility studies quantify the economic benefit relative to health gains.
  • Economic analyses are becoming an essential step for biomarker integration.

Conclusions:

  • Clinical utility is a prerequisite for a biomarker's economic viability.
  • Cost-utility studies, using metrics like QALY, are vital for assessing new biomarkers.
  • Economic evaluations represent a critical, final hurdle for the routine use of novel biomarkers.